Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/international-lung-cancer-study-involving-cu-medicine-reveals-that-combination-of-immune-drugs-and-chemotherapy-represents-new-treatment-regime-for-metastatic-nsclc-patients
https://www.med.cuhk.edu.hk/press-releases/international-lung-cancer-study-involving-cu-medicine-reveals-that-combination-of-immune-drugs-and-chemotherapy-represents-new-treatment-regime-for-metastatic-nsclc-patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Professor Tony Mok from The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) joined with international experts in lung cancer to investigate the effect of different immunotherapy drugs in combination with chemotherapy on metastatic non-small cell lung cancer (NSCLC). Through a randomised, open-label study, they found that combining immune drugs tremelimumab plus durvalumab with chemotherapy can significantly improve progression-free survival and overall survival, representing a potential new option in first-line metastatic NSCLC treatment. The findings have been published in the leading international medical journal Journal of Clinical Oncology

 

Combination of tremelimumab plus durvalumab with chemotherapy significantly improves treatment efficacy for metastatic NSCLC

 

Lung cancer is one of the most common cancers in the world, accounting for 1.8 million deaths every year. According to the Hong Kong cancer registry, lung cancer is the leading cause of cancer deaths and the most common cancer in the city, with more than 5,000 new cases every year. NSCLC accounts for over 80% of all lung cancers. Using immunotherapy alongside chemotherapy has proved promising in some recent studies for patients with metastatic NSCLC.

 

The international research team recruited 1,013 patients from 142 sites in 18 countries to join a Phase 3 study that compared treatment outcomes of combined immuno- and chemotherapy versus chemotherapy alone. They were randomly assigned to three treatment arms: immune checkpoint inhibitors tremelimumab plus durvalumab with chemotherapy (T+D+CT arm); durvalumab with chemotherapy (D+CT arm); or chemotherapy only (CT arm). (Please refer to table 1 in the appendix for details of study design.)

 

Results showed that treatment outcomes were better for patients who received combined immunotherapy with chemotherapy. In particular, the T+D+CT arm showed significant improvement compared to patients who only received chemotherapy, with a doubling of their 12-month progression-free survival rate, and an increase by 50% in their 24-month overall survival rate. (Please refer to table 2 and 3 in the appendix for full data.)

 

Prof Tony mok

Professor Tony Mok

Professor Tony Mok, Li Shu Fan Professor of Clinical Oncology and Chairman of CU Medicine’s Department of Clinical Oncology, said, “Our study provided a new treatment option for metastatic NSCLC patients. The use of tremelimumab alongside durvalumab with chemotherapy significantly improved progression-free survival and overall survival versus chemotherapy, without a clinically meaningful increase in tolerability burden. We are grateful to have obtained approval from the U.S. Food and Drug Administration to apply this new treatment regime for patients with metastatic NSCLC in the U.S.”

The PD-L1-negative subgroup has particular clinical relevance

 

Immune checkpoint inhibitors are a standard first-line therapy for advanced or metastatic NSCLC with PD-L1 expression, known as anti PD-1 checkpoint inhibitors. Durvalumab is one of them. However, patients with PD-L1-low or PD-L1-negative tumours are less likely to respond to anti PD-1 therapy, underling the need for new therapeutic strategies with immunotherapy combinations.

 

Professor Mok added, “The addition of immune drug tremelimumab, an anti-cytotoxic T-lymphocyte-associated antigen 4, extended clinical benefits to patients with PD-L1-negative tumours. These patients appeared to make the greatest gains in survival outcomes from this new combined therapy.” 

 

Table 1: Details of the three treatment arms

 

Treatment arm

(Number of patients)

 

T + D + CT* (338)

Patients received both tremelimumab 75mg plus durvalumab 1,500mg alongside platinum-based chemotherapy for up to four 21-day cycles, followed by durvalumab once every four weeks until their cancer progressed, and one additional tremelimumab dose.

D + CT* (338)

Patients received durvalumab 1,500mg plus chemotherapy for up to four 21-day cycles, followed by durvalumab once every four weeks until their cancer progressed.

CT* (337)

Patients received chemotherapy for up to six 21-day cycles.

*T: tremelimumab; D: durvalumab; CT: chemotherapy

 

Table 2: An overview of the median progression-free survival and 12-month progression-free survival rates

 

Treatment arm (Number of patients)

Median progression-free survival

12-month progression-free survival 

T + D + CT* (338)

6.2 months

26.6%

D + CT* (338)

5.5 months

24.4%

CT* (337)

4.8 months

13.1%

*T: tremelimumab; D: durvalumab; CT: chemotherapy

 

Table 3: An overview of the median overall survival and 24-month overall survival rate

 

Treatment arm

(Number of patients)

Median overall survival

24-month overall survival rate

T + D + CT* (338)

14 months

32.9%

D + CT* (338)

13.3 months

29.6%

CT* (337)

11.7 months

22.1%

*T: tremelimumab; D: durvalumab; CT: chemotherapy

More Press Releases

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
 CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Research
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK discovers a blood regulator linked to tumour microenvironment formation,  sparking a new therapeutic target for lung cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

Research
CUHK performs world’s first robotic-assisted bronchoscopic  microwave ablation of lung metastases

CUHK performs world’s first robotic-assisted bronchoscopic microwave ablation of lung metastases

Surgical advancement
CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

Research
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.